Vertex Pharmaceuticals Inc (VRTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vertex Pharmaceuticals Inc (VRTX) has a cash flow conversion efficiency ratio of 0.056x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.13 Billion) by net assets ($20.25 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see VRTX company net worth for the company's overall valuation and market capitalisation.
Vertex Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1991–2025)
This chart illustrates how Vertex Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Vertex Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vertex Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore VRTX cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mizuho Financial Group Inc.
NYSE:MFG
|
0.051x |
|
Siemens Energy AG
XETRA:ENR
|
0.218x |
|
Newmont Goldcorp Corp
NYSE:NEM
|
0.083x |
|
Iberdrola S.A.
MC:IBE
|
0.049x |
|
Bristol-Myers Squibb Company
NYSE:BMY
|
0.152x |
|
Honeywell International Inc
NASDAQ:HON
|
0.076x |
|
Prologis Inc
NYSE:PLD
|
0.023x |
|
Newmont Corporation
AU:NEM
|
0.108x |
Annual Cash Flow Conversion Efficiency for Vertex Pharmaceuticals Inc (1991–2025)
The table below shows the annual cash flow conversion efficiency of Vertex Pharmaceuticals Inc from 1991 to 2025. View today's stock price for Vertex Pharmaceuticals Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $18.67 Billion | $3.63 Billion | 0.195x | +748.08% |
| 2024-12-31 | $16.41 Billion | $-492.60 Million | -0.030x | -114.92% |
| 2023-12-31 | $17.58 Billion | $3.54 Billion | 0.201x | -32.22% |
| 2022-12-31 | $13.91 Billion | $4.13 Billion | 0.297x | +13.41% |
| 2021-12-31 | $10.10 Billion | $2.64 Billion | 0.262x | -30.12% |
| 2020-12-31 | $8.69 Billion | $3.25 Billion | 0.375x | +45.23% |
| 2019-12-31 | $6.09 Billion | $1.57 Billion | 0.258x | -9.96% |
| 2018-12-31 | $4.44 Billion | $1.27 Billion | 0.286x | -30.77% |
| 2017-12-31 | $2.04 Billion | $844.94 Million | 0.414x | +134.49% |
| 2016-12-31 | $1.34 Billion | $236.10 Million | 0.176x | +152.76% |
| 2015-12-31 | $1.09 Billion | $-365.43 Million | -0.334x | +28.46% |
| 2014-12-31 | $1.10 Billion | $-513.20 Million | -0.467x | -1129.56% |
| 2013-12-31 | $1.36 Billion | $-51.57 Million | -0.038x | -117.52% |
| 2012-12-31 | $1.23 Billion | $267.84 Million | 0.217x | +45.75% |
| 2011-12-31 | $965.51 Million | $143.74 Million | 0.149x | +111.81% |
| 2010-12-31 | $503.97 Million | $-635.44 Million | -1.261x | -223.29% |
| 2009-12-31 | $1.10 Billion | $-427.59 Million | -0.390x | +58.87% |
| 2008-12-31 | $238.87 Million | $-226.48 Million | -0.948x | -1.88% |
| 2007-12-31 | $271.30 Million | $-252.48 Million | -0.931x | -1994.95% |
| 2006-12-31 | $505.94 Million | $-22.48 Million | -0.044x | +93.82% |
| 2005-12-31 | $239.18 Million | $-172.05 Million | -0.719x | +82.07% |
| 2004-12-31 | $35.44 Million | $-142.16 Million | -4.011x | -361.47% |
| 2003-12-31 | $192.84 Million | $-167.62 Million | -0.869x | -313.72% |
| 2002-12-31 | $378.58 Million | $-79.54 Million | -0.210x | -1136.94% |
| 2001-12-31 | $475.35 Million | $-8.07 Million | -0.017x | +64.72% |
| 2000-12-31 | $345.76 Million | $-16.64 Million | -0.048x | +68.33% |
| 1999-12-31 | $209.19 Million | $-31.80 Million | -0.152x | -20.34% |
| 1998-12-31 | $246.20 Million | $-31.10 Million | -0.126x | -270.90% |
| 1997-12-31 | $276.00 Million | $-9.40 Million | -0.034x | +88.95% |
| 1996-12-31 | $130.80 Million | $-40.30 Million | -0.308x | -64.26% |
| 1995-12-31 | $85.30 Million | $-16.00 Million | -0.188x | -34.62% |
| 1994-12-31 | $105.50 Million | $-14.70 Million | -0.139x | -180.20% |
| 1993-12-31 | $49.50 Million | $8.60 Million | 0.174x | +243.91% |
| 1992-12-31 | $43.90 Million | $-5.30 Million | -0.121x | -152.08% |
| 1991-12-31 | $52.20 Million | $-2.50 Million | -0.048x | -- |
About Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with C… Read more